Altered drug sensitivities to anticancer agents in radiation-sensitive DNA repair deficient yeast mutants

Anticancer Res. Sep-Oct 1994;14(5A):1807-10.

Abstract

We studied whether cellular sensitivity to anticancer agents was correlated with a repair deficiency in three yeast epistasis groups of radiation sensitive mutants. All these mutants were hypersensitive to cisplatin and mitomycin C. By contrast, both rad51 and rad52 mutants deficient in double-strand breaks repair were hypersensitive to adriamycin and bleomycin, but the rad1 and rad10 mutants deficient in nucleotide excision repair were not. These results were confirmed by examining the cellular sensitivity of either revertants or strains carrying wild RAD+ protein expression plasmids to various drugs. Cellular damage by the above anticancer agents is discussed in relation to the DNA repair mechanisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Bleomycin / pharmacology
  • Cisplatin / pharmacology
  • DNA / genetics
  • DNA Damage
  • DNA Repair*
  • DNA, Fungal / metabolism
  • Doxorubicin / pharmacology
  • Drug Resistance / genetics
  • Drug Screening Assays, Antitumor
  • Mitomycin / pharmacology
  • Mutation
  • Phenotype
  • Radiation Tolerance
  • Saccharomyces cerevisiae / drug effects*
  • Saccharomyces cerevisiae / genetics*
  • Saccharomyces cerevisiae / radiation effects

Substances

  • Antineoplastic Agents
  • DNA, Fungal
  • Bleomycin
  • Mitomycin
  • Doxorubicin
  • DNA
  • Cisplatin